Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 27, 2024. 

NeurologyLive® Friday 5 — September 27, 2024

Tim Miller, MD, director of functional neurosurgery at the Marcus Neuroscience Institute, Baptist Health, provided commentary on the use of HIFU as a non-invasive treatment for patients with essential tremor and specific types of Parkinson disease.

Exploring the Treatment Possibilities and Functionality of High Intensity Focused Ultrasound

Videos

The consultant neurologist at Queen's Square MS Center in London gave his clinical viewpoint on the newest revision of the McDonald criteria for diagnosing patients with multiple sclerosis. [WATCH TIME: 3 minutes]

Perspectives on Updated McDonald Criteria to Transform MS Diagnosis: Wallace Brownlee, MBChB, PhD, FRACP

Innovative neurosurgical advances in imaging/mapping, robotic assistance, and extended reality enable surgeons to more precisely and effectively treat neurological conditions such as brain tumor, epilepsy, Parkinson Disease, and stroke, giving patients new hope and a chance for more successful outcomes.  

Expanding the Boundaries of Neurosurgical Care: Recent Advances Give Patients New Hope

, has been with the team since October 2019. Follow him on Twitter 

The chief research officer of the Muscular Dystrophy Association talked about what is to be expected at the 2025 MDA Conference, held March 16-19, in Dallas, Texas. [WATCH TIME: 5 minutes]

A Melting Pot of Strategies and Collaboration at the 2025 MDA Conference: Sharon Hesterlee, PhD

Staff neurologist, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic talked about a promising therapy that slows the progression of disability in non-relapsing secondary progressive multiple sclerosis. [WATCH TIME: 2 minutes]

The Promising Results of Tolebrutinib for Secondary Progressive Multiple Sclerosis Treatment: Robert J. Fox, MD

Director of Regulatory Affairs at the National MS Society.

Nicole M. Boschi, PhD, the director of regulatory affairs at the National MS Society, talked about the impact of the upcoming Medicare Part D and Medicare Advantage changes for the multiple sclerosis community. 

Important Changes Are Coming to Medicare in 2025: What You Need to Know to Help Your Patients

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

ECTRIMS 2024

MDS 2024

FEATURE: Long COVID’s Neurological Toll

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Expert Insights on Novel NMOSD Treatments

Treatment Options to Manage and Prevent Relapses in NMOSD

Video content above is prompted by the following:

What treatment options are available for NMOSD (Kümpfel 2024)?

Discuss options available for treatment of the acute phase and relapses and prevention of relapses.

How do the traditional and newer treatments target various aspects of NMOSD pathophysiology?

Three medical experts explore key insights on novel treatments for NMOSD, focusing on relapse management, disability accumulation, and the efficacy of new versus traditional therapies.

This discussion covers the factors leading to relapses and recurring attacks in NMOSD, how disease severity and relapses contribute to disability accumulation, and their impact on patients' quality of life.

Relapses and Disability Accumulation in NMOSD

This discussion examines how disability accumulation may be influenced by the use of less efficacious treatments, compares the efficacy of novel and traditional NMOSD agents in clinical practice, and reviews relapse rates associated with FDA-approved treatments versus off-label and older therapies.

Treatments With Higher Efficacy and Relapses in NMOSD

This discussion examines the 138-week data on ravulizumab for NMOSD, focusing on long-term relapse rates, and share practical tips for effective NMOSD management in clinical settings.

Ravulizumab Long-Term Data and Management of NMOSD

Jacqueline Nicholas, MD, MPH, discusses the evolution of NMOSD pathophysiology understanding and the critical role of the complement system in its development.

The Evolving Understanding of NMOSD Pathophysiology and the Role of Complement System

Jacqueline Nicholas, MD, MPH, discusses available treatment options for NMOSD, including management of acute phases, relapses, and symptom control, as well as how both traditional and newer therapies address different aspects of NMOSD pathophysiology.

 video series brings together pairs of expert clinicians and physicians to independently provide their insights on the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

Treatment Options to Manage and Prevent Relapses in NMOSD

EP: 1.Relapses and Disability Accumulation in NMOSD

EP: 2.Treatments With Higher Efficacy and Relapses in NMOSD

EP: 3.Ravulizumab Long-Term Data and Management of NMOSD

EP: 4.The Evolving Understanding of NMOSD Pathophysiology and the Role of Complement System

EP: 5.Treatment Options to Manage and Prevent Relapses in NMOSD